Axsome Therapeutics Announces Positive Outcome of Interim Analysis of STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant Depression
26 avr. 2018 07h00 HE
|
Axsome Therapeutics, Inc.
Independent Data Monitoring Committee recommends trial continuation Second interim analysis anticipated second half of 2018 for efficacy NEW YORK, April 26, 2018 (GLOBE NEWSWIRE) -- Axsome...
Axsome Therapeutics Hosts R&D Day Today with Key Opinion Leaders Focusing on AXS-05 and Unmet Needs in Depression, Alzheimer’s Disease Agitation, and Nicotine Dependence
24 avr. 2018 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, April 24, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of AXS-05 in Smoking Cessation
23 avr. 2018 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, April 23, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics to Host R&D Day with Key Opinion Leaders Focused on AXS-05 and Unmet Needs in Depression, Alzheimer’s Disease Agitation, and Nicotine Dependence
27 mars 2018 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, March 27, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Presents Scientific Rationale for the Development of AXS-05 at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics
12 mars 2018 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, March 12, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
07 mars 2018 07h00 HE
|
Axsome Therapeutics, Inc.
Interim analyses of STRIDE-1 and ADVANCE-1 trials of AXS-05 anticipated in 2018 Company to host conference call today at 8:00 AM Eastern NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- Axsome...
Axsome Therapeutics Announces Primary Endpoint Met in Phase 1 Trial of Next Generation Product Candidate AXS-09 Containing Chirally Pure Esbupropion and Dextromethorphan
26 févr. 2018 07h00 HE
|
Axsome Therapeutics, Inc.
Chirally pure and stable single enantiomers of bupropion achieved AXS-09 consists of esbupropion and dextromethorphan for CNS disorders Esbupropion is the chirally pure S-enantiomer of bupropion ...
Axsome Therapeutics to Present at 2018 BIO CEO & Investor Conference
05 févr. 2018 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Announces AXS-02 Independent Data Monitoring Committee Recommends Continuation of COAST-1 Trial and Discontinuation of CREATE-1 Trial
09 janv. 2018 07h00 HE
|
Axsome Therapeutics, Inc.
COAST-1 is a Phase 3 trial of AXS-02 in knee osteoarthritis associated with bone marrow lesions CREATE-1 is a Phase 3 trial of AXS-02 in complex regional pain syndrome Significant reduction in bone...
Axsome Therapeutics to Present at Biotech Showcase 2018
19 déc. 2017 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...